Response and palliation in a phase II trial of gemcitabine in hormone- refractory metastatic prostatic carcinoma

Annals of Oncology

Volumn 11, Issue 2, 2000, Pages 183-188

  Morant, R ^a   Bernhard, J ^b   Maibach, R ^b   Borner, M ^b   Fey, M F ^b   Thurlimann B ^b   Jacky, E ^b   Trinkler, F ^b   Bauer, J ^b   Zulian, G ^b   Hanselmann, S ^b   Hurny C ^b   Hering, F ^b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b NONE

Author keywords

Gemcitabine; Gormone refractory prostate cancer; Pain; Palliative endpoints; Prostate specific antigen; Quality of life

Indexed keywords

ANALGESIC AGENT; GEMCITABINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEVER; HORMONE RESISTANCE; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HORMONES; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PAIN MEASUREMENT; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0034055172     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008332724977     Document Type: Article

References (22)

1. Catalona W. Management of cancer of the prostate. N Engl J Med 1994; 331: 996-1004.
2. Hudes GR, Nathan F, Khater C et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-63.
3. Dimopooulos MA, Panopouolos C, Bamia C et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50: 754-8.
4. Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997; 24: 15-72.
5. Smith DC, Pienta KJ. The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone-refractory prostate cancer. Urol Clin North 1997; 24: 433-7.
6. Andriole GL. Serum prostate-specific antigen: Expanding its role as a measure of treatment response in patients with prostate cancer. J Clin Oncol 1993; 11: 596-7.
7. Kelly WM, Scher HI, Mazumdar M et al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607-15.
8. Curran D, Fossa S, Aaronson N et al. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997; 33: 1809-14.
9. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985; 3: 1013-21.
10. Tannock IF, Gospodarowicz M, Meakin W et al. Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590-7.
11. Moore MJ, Osoba D, Murphy K et al. Use of palliative end points to evaluate the effects of Mitoxantrone and low-dose Prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994; 12: 689-94.
12. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
13. Jungi WF, Bernhard J, Hürny C et al. Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer 1998; 6: 462-8.
14. Schmid HP, Maibach R, Bernhard J et al. A phase II study of oral idaruhicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research. Cancer 1997; 79: 1703-17.
15. Burris HA, Morre AJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-13.
16. Cronauer MV, Klocker H, Talasz H et al. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate 1996; 28 (3): 172-81.
17. Morant R, Ackermann D, Trinkler F et al. Gemcitabine in hormone-refractory metastatic prostatic carcinoma: A phase II study of the SAKK. Proc Annu Meet Am Soc Clin Oncol 1997; 16: A1109.
18. Morant R, Bernhard J, Maibach R et al. for the Swiss Group for Clinical Cancer Research (SAKK). Quality of life in a phase II trial of Gemcitabine in hormone-refractory metastatic prostatic carcinoma. Proc Annu Meet Am Soc Clin Oncol 1998; 17: A1301.
19. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
20. Hürny C, Bernhard J, Bacchi M et al. The perceived adjustment to chronic illness scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1993; 1: 200-8.
21. King MT. The interpretation of scores from the EORTC quality of life questionnarie QLQ-C30. Qual Life Res 1996; 5: 555-67.
22. Dowling AJ, Panzarella T, Tannock IF. Relationship between changes in serum prostatic specific antigen (PSA) and palliative response following treatment of symptomatic hormone-refractory prostate cancer (HRPC). Proc Annu Meet Am Soc Clin Oncol 1998; 17: A1248.